| 1 |
Development of a triple-function improved anti-GD2 CAR natural killer cell-based treatment for recurrent glioblastoma derived from induced pluripotent stem cells |
| Cell therapies |
Glioblastoma |
GD2 |
Preclinical |
Vigencell |
RS-2025-25455212 |
|
| 2 |
Non-clinical trial and IND approval of high efficiency BCMA CAR-T cell therapy |
| Cell therapies |
Multiple Myeloma |
BCMA |
Preclinical |
nSAGE |
RS-2025-25454748 |
|
| 3 |
Clinical Phase 1 Development of BVAC-E6E7 for HPV16 and/or HPV18 Positive Unresectable Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma |
| Cell therapies |
HPV16/18 positive HNSCC |
HPV16/18 E6, E7 protein |
Phase 1 |
Cellid |
RS-2025-25451121 |
|
| 4 |
Development of BCMA-targeting CAR-MILs for Treatment of Relapsed/Refractory Multiple Myeloma |
| Cell therapies |
Multiple Myeloma |
MILs (골수침윤림프구) |
Preclinical |
VAXCELLBIO CO., LTD. |
RS-2025-02223662 |
|
| 5 |
Development of iPSC-derived NK cell therapy to induce chemotaxis of immune cells for liver cancer treatment |
| Cell therapies |
Liver cancer |
IL-7/CCL19 |
Lead |
TSD Life Sciences Inc. |
RS-2025-02213692 |
|
| 6 |
Phase 1 IND Approval for Next-Generation Functionally Enhanced Tumor Infiltrating Lymphocyte (TIL) Cell Therapy for Recurrent Ovarian Cancer |
| Cell therapies |
Ovarian cancer |
MUC-1 peptide stimulation |
Preclinical |
CHA Biotech Co., Ltd |
RS-2025-02213314 |
|
| 7 |
Development of CD5 CAR-NK therapeutics for treating NK and T-cell malignancies |
| Cell therapies |
NK and T-cell malignancies |
CD5 |
Phase 1 |
GC Cell |
RS-2024-00508039 |
|
| 8 |
Non-Clinical Study of CD19 CAR-NK for Phase 1 Clinical Trial for Hematologic Malignancy |
| Cell therapies |
B- cell lymphoma |
CD19 |
Preclinical |
GC Cell |
RS-2024-00463361 |
|
| 9 |
A novel monobody & scFv-based CAR-T for solid cancer |
| Cell therapies |
Solid tumor (Ovarian Cancer) |
EphA2, PD-L1 |
Candidate |
VAXCELL-BIO CO., LTD |
RS-2024-00341192 |
|
| 10 |
Lead Optimization of Solid tumor-targeting MUC1-CAR-T Cell Therapy Candidate Utilizing AviCLIP-CAR Technology |
| Cell therapies |
MUC1 positive solid cancer |
MUC1 |
Candidate |
TiCARos. Inc |
RS-2024-00337759 |
|
| 11 |
Study to derive a final lead candidate of TCR-T cell therapy for the treatment of EGFR L858R mutant lung cancer patients |
| Cell therapies |
EGFR L858R mutant lung cancer |
pMHC |
Candidate |
DAAN Biotherapeutics |
RS-2024-00336489 |
|
| 12 |
Phase 2 IND approval of high purity immune cell therapy (CBT101) of frozen formulation for recurrent glioblastoma, improved through process advancement |
| Cell therapies |
Recurrent glioblastoma |
|
Preclinical |
CHABIOTECH CO.,LTD |
RS-2024-00334310 |
|
| 13 |
Phase 2 clinical study of innovative CD19-targeted CAR-T |
| Cell therapies |
Cancer |
CD19 |
Phase 2 |
Ab Clon Inc. |
RS-2024-00332815 |
|
| 14 |
Development of universal iPSC.NK (induced pluripotent stem cellderived NK cell therapy) with higher ability of immune evasion and persistence for the treatment of solid cancer |
| Cell therapies |
Liver cancer |
IL.15RF, HLA.G |
Candidate |
Therabest Co., Ltd |
RS-2023-00283732 |
|
| 15 |
Autologous 4th generation GPC3 CAR.T clinical study for advanced hepatocellular carcinoma |
| Cell therapies |
Liver cancer |
GPC3 |
Phase 1 |
Eutilex Co.,Ltd. |
RS-2023-00283610 |
|
| 16 |
IL.21 on/off switch.armored solid tumor.targeting TET KO CAR.T cell therapy |
| Cell therapies |
Solid Tumor |
IL.21 |
Hit |
Seoul National University |
RS-2023-00282907 |
|
| 17 |
Development of HLA.G CAR.T cell therapy targeting HLA.G.positive solid tumors |
| Cell therapies |
Solid tumor |
HLA.G |
Preclinical |
HK Inno. N |
RS-2023-00282541 |
|
| 18 |
TC011: Clinical Phase I Trial Evaluating Safety, Pharmacokinetics, DLT, MTD, Efficacy and RP2D of TC011, a CD19.Targeted CAR.T Therapyin Relapsed or Refractory B.Cell Non.Hodgkin Lymphoma Patients |
| Cell therapies |
B cell lymphoma |
CD19 |
Phase 1 |
TICAROS |
RS-2023-00258721 |
|
| 19 |
Efficacy evaluation of optimized CAR-T therapy against refractory epithelial ovarian cancer |
| Cell therapies |
Ovarian cancer |
메소텔린 |
Candidate |
CellenGene |
RS-2023-00217215 |
|
| 20 |
Development of first-in-class endoglin-targeted CAR-NK and its application for inducing immune-friendly microenvironment |
| Cell therapies |
Relapsed and Refractory Pancreatic cancer |
Endoglin |
Lead |
Korea Institute of Science and Technology |
RS-2022-00166088 |
|
| 21 |
Secured ex vivo gene therapy candidate for the treatment of solid tumor |
| Cell therapies |
Glioblastoma |
Cytosine Deaminase |
Candidate |
CELL & BRAIN Co., Ltd |
RS-2022-00165974 |
|
| 22 |
YYB-103 |
| Cell therapies |
Glioblastoma |
IL13Rα2 |
Phase 1 |
CellabMED |
HN22C0592 |
|
| 23 |
Development of personalized solid cancer therapy with neoantigen targeted TCR-T cells |
| Cell therapies |
Solid Tumor |
Neoantigen |
Candidate |
Neogen TC |
HN22C0269 |
|
| 24 |
Development of L1CAM targeted CAR-T therapy for recurrent ovarian cancer |
| Cell therapies |
Ovarian Cancer |
L1CAM |
Preclinical |
Cartexell Inc |
HN22C0250 |
|
| 25 |
Phase I clinical study of innovative CD19-targeted CAR-T |
| Cell therapies |
Non-Hodgkin Lymphoma |
CD19 |
Phase 1 |
AbClon Inc. |
HN22C0009 |
|
| 26 |
Development of candidate compounds for
Probe & Catch CAR-T cells targeting
CD40-positive hematologic tumors |
| Cell therapies |
Blood tumor |
CD40 |
Candidate |
TiCARos Inc |
HN21C0764 |
|
| 27 |
Clinical trial and drug approval of the next generation CD19 CAR-T designed to overcome immune-suppressive environment |
| Cell therapies |
Non-small cell lymphoma |
CD19 |
Phase 1 |
Curocell Inc. |
HN21C0653 |
|
| 28 |
Development of lead compounds for solid tumor-targeting CC12 platform-based reinforced B7H3 CAR-T cells |
| Cell therapies |
Solid Tumor |
B7-H3, IL-12 |
Hit |
Seoul National University |
HN21C0232 |
|
| 29 |
Development of CAR T cell safety system using chemical switch |
| Cell therapies |
Blood Cancer |
CAR-DEGRON-T |
Hit |
KRICT(Korea Research Institute of Chemical Technology) |
HN21C0226 |
|
| 30 |
Development and optimization of lead CD5 CAR-NK for T cell malignancies |
| Cell therapies |
Blood Cancer |
CD5 |
Lead |
Korea Research Institute of Bioscience and Biotechnology |
HN21C0117 |
|